Highlights Transcenta Holding Limited

Equities

6628

KYG9005B1041

Market Closed - Hong Kong S.E. Other stock markets 09:08:09 16/05/2024 BST			5-day change	1st Jan Change
1.8 ^HKD	+1.12%		-4.76%	-49.86%

04-30	Transcenta Holding Limited Announces Board and Nomination Changes	CI
04-09	Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic	04-09	MT
Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial	04-08	CI
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging	12-13	CI
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain	23/10/23	CI
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients	03/10/23	CI
Transcenta Widens Loss in H1	23/08/23	MT
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023	22/08/23	CI
Transcenta Moves to Phase II Trial of Osteoporosis Drug	31/07/23	MT
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)	31/07/23	CI
Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab	07/07/23	CI
Transcenta Holding Limited Presents Pfs Data by Cldn18.2 Expression Level from Phase I/Ii Study of Osemitamab Plus Capecitabine and Oxaliplatin as the First-Line Treatment of Advanced G/Gej Cancer	30/06/23	CI
Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin	30/06/23	CI
Transcenta Holding Limited commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on June 9, 2023.	09/06/23	CI
Transcenta Holding Limited's Equity Buyback announced on September 14, 2022, has expired.	08/06/23	CI
Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab	05/06/23	CI
Transcenta Holding Limited Announces Encouraging Phase I Clinical Data of TST002 in Chinese Patients with Reduced Bone Mineral Density	16/05/23	CI
Transcenta Holding Limited to Present Two Clinical Trial Progress At Asco 2023	08/05/23	CI
Transcenta Holding Limited Announces Completion of Enrollment in COHorts C and G of China Phase II Study of Osemitamab in Combination with Capecitabine and Oxaliplatin	02/05/23	CI
Tranche Update on Transcenta Holding Limited's Equity Buyback Plan announced on September 14, 2022.	27/04/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Transcenta Holding Limited

Equities

6628

KYG9005B1041

Highlights

Filters